|
Aurobindo Pharma Limited announced its consolidated financial results for the quarter ended June 30, 2026.
The company's revenue from operations increased by 16.3% YoY to Rs. 9,150 crore with growth across businesses, while net profit for the quarter stood at Rs. 1,032 crore.
The company's US revenue increased by 8.1% YoY to Rs. 3,770 crore primarily driven by volume gains and new launches, partially offset by no transient product sales, while API revenues increased 14.6% YoY, despite sequential seasonal softness in the antibiotics portfolio, and contributed 11.5% of consolidated revenue.
Commenting on the company’s performance, K Nithyananda Reddy, vice-chairman and managing director of the company said: “We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio. While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long-term growth objectives and create sustained value for our stakeholders.”
|